LNTH vs. TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, and BPMC
Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.
Lantheus vs. Its Competitors
Lantheus (NASDAQ:LNTH) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.
Lantheus has a net margin of 16.55% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Lantheus' return on equity.
Lantheus has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
99.1% of Lantheus shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 2.0% of Lantheus shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Lantheus has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
In the previous week, Teva Pharmaceutical Industries had 10 more articles in the media than Lantheus. MarketBeat recorded 20 mentions for Teva Pharmaceutical Industries and 10 mentions for Lantheus. Lantheus' average media sentiment score of 0.85 beat Teva Pharmaceutical Industries' score of 0.61 indicating that Lantheus is being referred to more favorably in the media.
Lantheus currently has a consensus price target of $130.50, suggesting a potential upside of 64.32%. Teva Pharmaceutical Industries has a consensus price target of $24.13, suggesting a potential upside of 44.89%. Given Lantheus' higher probable upside, analysts plainly believe Lantheus is more favorable than Teva Pharmaceutical Industries.
Summary
Lantheus beats Teva Pharmaceutical Industries on 10 of the 17 factors compared between the two stocks.
Get Lantheus News Delivered to You Automatically
Sign up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lantheus Competitors List
Related Companies and Tools
This page (NASDAQ:LNTH) was last updated on 7/2/2025 by MarketBeat.com Staff
